MGL-3196

resmetirom · Madrigal Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for MGL-3196, covering 2016-08-30 to 2025-12-23. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) [Phase 2]